Background: Malaria remains a leading cause of mortality in sub-Saharan Africa (including Sudan). C-reactive protein (CRP) is useful as a marker of severity in malaria. African studies have shown that serum CRP levels correlate with parasite burden and complications in malaria, especially falciparum. However, there are no data on CRP levels in Sudanese malaria patients. This study aims to evaluate the association between CRP levels with comorbidities, species, and complications of severe malaria Subjects and Methods: A cross-sectional study enrolled 65 severe malaria patients at Khartoum state hospitals during the period from April to June2021. Manifestations of severe malaria were defined according to WHO criteria. Data regarding demographics, presenting symptoms & signs, laboratory investigations, complications, length of hospital stay and outcomes were collected. CRP was classified as elevated when the measured level was >10 mg/l. Results: Among 65 patients, 33(50.8%) were females and 32(49.2%) were males, and mean age was 48±21 years. The main manifestation of severe malaria diagnosis criteria was anemia in 26(40%) patients. Most of the patients had density 1+ (n=53; 81.5%) and were infected by P. falciparum (n=61; 93.8%). The overall case fatality rate for malaria was 8% (n=15 patients). The mean of CRP was 72±57 mg/L and 84% (n=55) of patients had elevated levels above 10 mg/L (ranged from 10-100 mg/L in 52%, and above 100 mg/L in 32%). The elevated CRP levels were significantly DM (P= 0.048), high malaria parasite density in blood film (P= 0.001), P. falciparum (P= 0.33), presence of complications (P= 0.001) and death (P= 0.003) Conclusion: Elevated CRP levels were found in a considerable proportion of severe malaria patients. CRP is an effective biomarker in assessing malaria severity and poor prognosis in term of complications development and mortality.
Background: Diabetes mellitus is a major health issue that is one of the leading causes of cardiovascular disease. Recent studies have found a link between uncontrolled diabetes and cardiovascular disease, with dyslipidaemia predicting glycated-hemoglobin (HbA1c), which could be a major contributor to type 2 diabetes complications and etiology. Objectives: The objective of present study was estimate lipid profiles among control and uncontrolled type 2 diabetic patients. Subjects and Methods: Analytical case control based study, One hundred twenty participate were included in study, 70 patients with DM as case group refer to Abuagala Center and difference follow up diabetic center and 50 non diabetic subjects taken as control group males and females their age between 20 to 80 years. Fasting blood glucose (FBG), blood HbA1c, and serum lipid parameters were measured by CobseC311 from Roche instrument. Data was analyzed using SPSS version 22, which expressed as (mean±SD) with p.value. Result:Among120 participant the levels of fasting blood glucose,blood HbA1c,and Triglyceridewereincreased significantly in T2DM (161.7±72.5mg/dl), (8.88±3.9 %), (121±61.9 mg/dl)when compare with control group(91.28±13.9), (5.7±0.50), (80±11.7) with P.value (0.000),while total Cholesterol, High Density Lipoprotein, and Low Density Lipoprotein were not significant different in T2DM when compared with control group. There was weak positive correlation between HbA1c with FBG, CHOL, LDL, and HDL (r = 0.207, P =0.089, r = 0.186, P =0.124, r = 0.167, P =0.168, r = 0.308, P =0.01) respectively, while TG hadweak negative correlation (r =- 0.146, P =0.228). Conclusion: The results indicated to considerable increase in the lipid profile levels in type two diabetic patients when compared with healthy controls group which may lead to increase in coronary risk factors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.